NCT04577469View on ClinicalTrials.gov

Bioequivalence Study of Sulfadoxine/ Pyrimethamine Tablets in Healthy Subjects Under Fasting Conditions

PHASE1UnknownINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Bioequivalence
Interventions
DRUG

Maldox tablets

500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition

DRUG

G-COSPE® tablets

500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition

Sponsors
All Listed Sponsors
lead

Emzor Pharmaceutical Industries Limited

INDUSTRY